ES8405621A1 - Una inmunopreparacion tumoral. - Google Patents
Una inmunopreparacion tumoral.Info
- Publication number
- ES8405621A1 ES8405621A1 ES521279A ES521279A ES8405621A1 ES 8405621 A1 ES8405621 A1 ES 8405621A1 ES 521279 A ES521279 A ES 521279A ES 521279 A ES521279 A ES 521279A ES 8405621 A1 ES8405621 A1 ES 8405621A1
- Authority
- ES
- Spain
- Prior art keywords
- plasma
- tumor
- prepared
- compositions
- normal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
METODO PARA LA PRODUCCION DE UNA INMUNOPREPARACION TUMORAL.CONSISTE EN: A) SOMETER EL PLASMA, PROCEDENTE DE UNA PERSONA NORMAL O PORTADOR DE UN TUMOR Y CON LAS SIGUIENTES PROPIEDADES: 1) CONSTITUIDO POR IGC E IGM; 2) SE PRODUCE UNION A CLQ EN LAS FRACCIONES QUE SEDIMENTAN MAS ALLA DE 7S EN UN GRADIENTE DE DENSIDADES DE SACAROSA; 3) PRODUCE REACCIONES TUMORICIDAS AL INFUNDIRSE EN LA PERSONA PORTADORA; 4) PRESENTA MENORES NIVELES DE IGC, IGM E INMUNOCOMPLEJOS Y MAYOR UNION A CLQ QUE EL EFLUENTE DE INMUNOGLOBULINA ENRIQUECIDA NO TRATADO; Y 5) PRESENTA TITULOS DE ANTICUERPOS DEL TUMOR SUPERIORES A 20.000 CUANDO PROCEDE DE UNA PERSONA PORTADORA DEL TUMOR, A UN CAMPO ELECTRICO Y A UNA CORRIENTE PARA OBTENER A PARTIR DEL PLASMA UN EFLUENTE CON UNA FRACCION ENRIQUECIDA QUE CONTIENE INMUNOGLOBULINAS; B) SOMETER EL EFLUENTE A ACIDULACION O A ALCALINIZACION PARA DISOCIAR LOS COMPLEJOS ANTIGENOS-ANTICUERPO Y LIBERAR ASI LOS ANTICUERPOS ESPECIFICOS DEL TUMOR; C) NEUTRALIZAR EL EFLUENTE; Y D) FILTRAR ELEFLUENTE PARA SEPARARLO DE LOS PRECIPITADOS.TIENE APLICACION PARA EL TRATAMIENTO DEL CANCER COMO LINFOMAS Y TUMORES SOLIDOS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36643682A | 1982-04-07 | 1982-04-07 | |
| US47236283A | 1983-03-11 | 1983-03-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES8405621A1 true ES8405621A1 (es) | 1984-06-16 |
| ES521279A0 ES521279A0 (es) | 1984-06-16 |
Family
ID=27003359
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES521279A Granted ES521279A0 (es) | 1982-04-07 | 1983-04-06 | Una inmunopreparacion tumoral. |
| ES528121A Expired ES8601703A1 (es) | 1982-04-07 | 1983-12-16 | Un metodo de produccion de una preparacion de proteina a-igg |
| ES528118A Granted ES528118A0 (es) | 1982-04-07 | 1983-12-16 | Un metodo de produccion de una preparacion de inmunoglobulina tumoral |
| ES528120A Granted ES528120A0 (es) | 1982-04-07 | 1983-12-16 | Un metodo de produccion de una preparacion de plasma activada con zymosan |
| ES528119A Granted ES528119A0 (es) | 1982-04-07 | 1983-12-16 | Un metodo de produccion de una preparacion de proteina a-igg |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES528121A Expired ES8601703A1 (es) | 1982-04-07 | 1983-12-16 | Un metodo de produccion de una preparacion de proteina a-igg |
| ES528118A Granted ES528118A0 (es) | 1982-04-07 | 1983-12-16 | Un metodo de produccion de una preparacion de inmunoglobulina tumoral |
| ES528120A Granted ES528120A0 (es) | 1982-04-07 | 1983-12-16 | Un metodo de produccion de una preparacion de plasma activada con zymosan |
| ES528119A Granted ES528119A0 (es) | 1982-04-07 | 1983-12-16 | Un metodo de produccion de una preparacion de proteina a-igg |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0091784B1 (es) |
| AU (2) | AU569467B2 (es) |
| CA (1) | CA1230555A (es) |
| DE (1) | DE3374756D1 (es) |
| DK (1) | DK154283A (es) |
| ES (5) | ES521279A0 (es) |
| FI (1) | FI831169L (es) |
| GB (2) | GB2119803B (es) |
| GR (1) | GR78514B (es) |
| NO (5) | NO831223L (es) |
| PT (1) | PT76505B (es) |
| RO (3) | RO89498A (es) |
| ZW (1) | ZW7583A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2161813B (en) * | 1984-07-20 | 1988-07-13 | Michiko Koga | Anti-tumor agent |
| GB9013872D0 (en) * | 1990-06-21 | 1990-08-15 | Inst Tecnologico Y Cientifico | Use of protein a and polypeptide components thereof in the treatment of tumours |
| AU6498494A (en) * | 1993-04-08 | 1994-11-08 | Board Of Regents, The University Of Texas System | Model for gonococcal infection |
| GB2422311A (en) * | 2005-01-20 | 2006-07-26 | Martin Lister | Treatment of blood to cure disease |
| DE102005012594A1 (de) | 2005-03-18 | 2006-09-21 | Bayer Technology Services Gmbh | Elektrofiltrationsverfahren |
| MX2011012094A (es) * | 2009-05-14 | 2012-03-26 | Oatmeal Biotechnologies Group L L C | Tecnologias de plataforma para enfermedades que se presentan espontaneamente. |
| EP4353320A3 (en) * | 2016-04-28 | 2024-05-15 | Alkahest, Inc. | Blood plasma and plasma fractions as therapy for tumor growth and progression |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4132769A (en) * | 1974-10-30 | 1979-01-02 | Osther Kurt B | Cancer antigen, cancer therapy, and cancer diagnosis |
| US4146603A (en) * | 1977-02-18 | 1979-03-27 | Research Corporation | Tumor specific glycoproteins and method for detecting tumorigenic cancers |
| FI791551A (fi) * | 1978-05-17 | 1979-11-18 | Benzon As Alfred | Renad cancer associerad protein |
-
1983
- 1983-03-25 ZW ZW75/83A patent/ZW7583A1/xx unknown
- 1983-03-25 AU AU12865/83A patent/AU569467B2/en not_active Ceased
- 1983-04-04 GR GR70987A patent/GR78514B/el unknown
- 1983-04-06 ES ES521279A patent/ES521279A0/es active Granted
- 1983-04-06 RO RO83114843A patent/RO89498A/ro unknown
- 1983-04-06 RO RO83110576A patent/RO86661A/ro unknown
- 1983-04-06 PT PT76505A patent/PT76505B/pt unknown
- 1983-04-06 DE DE8383301945T patent/DE3374756D1/de not_active Expired
- 1983-04-06 FI FI831169A patent/FI831169L/fi not_active Application Discontinuation
- 1983-04-06 RO RO83114841A patent/RO89496A/ro unknown
- 1983-04-06 EP EP83301945A patent/EP0091784B1/en not_active Expired
- 1983-04-06 GB GB08309348A patent/GB2119803B/en not_active Expired
- 1983-04-06 NO NO831223A patent/NO831223L/no unknown
- 1983-04-06 CA CA000425324A patent/CA1230555A/en not_active Expired
- 1983-04-07 DK DK154283A patent/DK154283A/da not_active IP Right Cessation
- 1983-12-16 ES ES528121A patent/ES8601703A1/es not_active Expired
- 1983-12-16 ES ES528118A patent/ES528118A0/es active Granted
- 1983-12-16 ES ES528120A patent/ES528120A0/es active Granted
- 1983-12-16 ES ES528119A patent/ES528119A0/es active Granted
-
1984
- 1984-04-13 NO NO841497A patent/NO841497L/no unknown
- 1984-04-13 NO NO841498A patent/NO841498L/no unknown
- 1984-04-13 NO NO841495A patent/NO841495L/no unknown
- 1984-04-13 NO NO841496A patent/NO841496L/no unknown
-
1985
- 1985-04-30 GB GB08510892A patent/GB2163164B/en not_active Expired
-
1988
- 1988-05-04 AU AU15600/88A patent/AU1560088A/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL254399A1 (en) | Method of isolating a neoplasm necrosis effecting factor | |
| GR3006492T3 (es) | ||
| AU4992985A (en) | Method and system for removing immunosuppressive components from the blood of mammals | |
| IE830934L (en) | 1,8-diaza-and 1,5,8-triazanaphthalene derivatives | |
| DK545584A (da) | Enzym-resistente immonumodulatoriske peptider | |
| ATE232394T1 (de) | Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs | |
| DE3173016D1 (en) | Preparations for the treatment of dermatoses | |
| ES8503950A1 (es) | Un metodo de produccion de una preparacion de plasma activada con zymosan | |
| DE3165965D1 (en) | Blood-coagulation-promoting products and methods of preparing them | |
| ES8502998A1 (es) | Procedimiento para la preparacion de nuevas b-carbolinas substituidas. | |
| DK241684A (da) | Fremgangsmaade til fremstilling af et antithrombin iii-heparin- eller antithrombin iii-heparinoidkoncentrat | |
| EP0325129A3 (en) | Disubstituted pyridines | |
| DE3685484D1 (es) | ||
| KR950700684A (ko) | 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use) | |
| ES2012547A6 (es) | Procedimiento para preparar una composicion farmaceutica que contiene metaloporfirinas. | |
| IT1169788B (it) | Procedimento per preparare composizioni contenenti gamma globulina | |
| Nagel et al. | Resistance of tumour cells to chemotherapy: importance of host defence factors | |
| Thomas et al. | Refractory and relapsing Hodgkin's disease: Role of high-dose chemotherapy with bone marrow transplantation | |
| Okuhara | Tumor Immunity Part 2. An Attempt at Immuno-Prophylaxis against Induction of DAB-Hepatoma | |
| JPS5758630A (en) | Interferon inducer | |
| GB1254948A (en) | Antivirial substance | |
| Thar et al. | Hodgkin's disease: Recurrence as related to size of disease, dose, and number of sites involved |